DAVID LINDEN: Open Payments
NPI 1821062324 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,876 in 85 payments from 13 companies in 2025. Trend: 2023 $1,257 · 2024 $1,806 · 2025 $1,876
Food & beverage: $1,876
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 17 | $437 |
| Otsuka America Pharmaceutical, Inc. | 20 | $370 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $254 |
| Alkermes, Inc. | 8 | $218 |
| Lundbeck LLC | 11 | $160 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $89 |
| Teva Pharmaceuticals USA, Inc. | 5 | $76 |
| Janssen Pharmaceuticals, Inc | 4 | $70 |
| Forte Bio-Pharma LLC | 3 | $55 |
| Neurocrine BioSciences, Inc. | 2 | $46 |
Products named: REXULTI, COBENFY, CAPLYTA, ARISTADA, RELISTOR, UZEDY, INGREZZA, LOREEV XR.
Industry payments across NV — which companies pay providers there.
